January 20, 2022
Article
Checkpoint inhibitors may have clinical utility in BTC based on immunogenic features of the disease; however, limited clinical activity has been observed with single-agent therapy in the advanced setting.
Pending FDA approval, the dual immunotherapy combination could provide patients with a new treatment option which would not require any further safety requirements prior to initiation.
January 19, 2022
Janelle Wagner, RN, OCN, Senior Manager of Patient Navigation Program for Community Sites, discusses the challenges and rewards of nurse navigation in oncology.
January 18, 2022
A supplemental biologics license application has been granted to trastuzumab deruxtecan-nxki for the treatment of adult patients with select HER2-positive breast cancer.
As the HPV vaccine becomes more prevalent, cervical cancer rates are expected to decrease significantly by 2030. However, this trend may differ across socioeconomic communities.
January 17, 2022
A patient-reported outcome survey highlighted quality-of-life gaps in breast cancer survivorship.
January 16, 2022
Ibrutinib plus rituximab is effective, easy to administer, and removes the need for chemotherapy in older patients, say experts.
January 15, 2022
Podcast
In this episode of “The Vitals,” 2 veteran oncology nurses discuss the value of mentorship—particularly for novice nurses.
January 14, 2022
An expert discusses the implications of a subgroup analysis of the DESTINY-BREAST03 trial, which highlighted the efficacy of trastuzumab deruxtecan in HER2-positive metastatic breast cancer.
Oral decitabine, an oral fixed-dose of combination decitabine and CDA inhibitor cedazuridine, is an FDA-approved therapy for patients with lower-risk myelodysplastic syndromes.
